Genome-wide mapping of histone modifications mediated by the polycomb-group complexes in fetal liver and adult bone marrow hematopoietic progenitor cells

2013 ◽  
Vol 41 (8) ◽  
pp. S27
Author(s):  
Motohiko Oshima ◽  
Satoru Miyagi ◽  
Shuhei Koide ◽  
Yutaka Suzuki ◽  
Atsushi Iwama
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Histone Modifications ◽  
Fetal Liver ◽  
Polycomb Group ◽  
Hematopoietic Progenitor Cells ◽  
Hematopoietic Progenitor ◽  
Genome Wide ◽  
Polycomb Group Complexes ◽  
Adult Bone

Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells

Development ◽  
2002 ◽  
Vol 129 (8) ◽  
pp. 2003-2013 ◽  
Author(s):  
Maria Teresa Mitjavila-Garcia ◽  
Michel Cailleret ◽  
Isabelle Godin ◽  
Maria Manuela Nogueira ◽  
Karine Cohen-Solal ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Fetal Liver ◽  
Hematopoietic Cells ◽  
Embryonic Stem ◽  
Yolk Sac ◽  
Embryoid Bodies ◽  
Hematopoietic Progenitor Cells ◽  
Hematopoietic Progenitors ◽  
Hematopoietic Progenitor

In this study, we have characterized the early steps of hematopoiesis during embryonic stem cell differentiation. The immunophenotype of hematopoietic progenitor cells derived from murine embryonic stem cells was determined using a panel of monoclonal antibodies specific for hematopoietic differentiation antigens. Surprisingly, the CD41 antigen (αIIb integrin, platelet GPIIb), essentially considered to be restricted to megakaryocytes, was found on a large proportion of cells within embryoid bodies although very few megakaryocytes were detected. In clonogenic assays, more than 80% of all progenitors (megakaryocytic, granulo-macrophagic, erythroid and pluripotent) derived from embryoid bodies expressed the CD41 antigen. CD41 was the most reliable marker of early steps of hematopoiesis. However, CD41 remained a differentiation marker because some CD41– cells from embryoid bodies converted to CD41+ hematopoietic progenitors, whereas the inverse switch was not observed. Immunoprecipitation and western blot analysis confirmed that CD41 was present in cells from embryoid bodies associated with CD61 (β3 integrin, platelet GPIIIa) in a complex. Analysis of CD41 expression during ontogeny revealed that most yolk sac and aorta-gonad-mesonephros hematopoietic progenitor cells were also CD41+, whereas only a minority of bone marrow and fetal liver hematopoietic progenitors expressed this antigen. Differences in CD34 expression were also observed: hematopoietic progenitor cells from embryoid bodies, yolk sac and aorta-gonad-mesonephros displayed variable levels of CD34, whereas more than 90% of fetal liver and bone marrow progenitor cells were CD34+. Thus, these results demonstrate that expression of CD41 is associated with early stages of hematopoiesis and is highly regulated during hematopoietic development. Further studies concerning the adhesive properties of hematopoietic cells are required to assess the biological significance of these developmental changes.

scholarly journals Analysis and Characterization of Hematopoietic Progenitor Cells from Fetal Bone Marrow, Adult Bone Marrow, Peripheral Blood, and Cord Blood

1999 ◽  
Vol 46 (2) ◽  
pp. 163-169 ◽  
Author(s):  
Ai Guo Wu ◽  
Maria Michejda ◽  
Amitabha Mazumder ◽  
Kenneth R Meehan ◽  
Frederick A Menendez ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cord Blood ◽  
Progenitor Cells ◽  
Peripheral Blood ◽  
Hematopoietic Progenitor Cells ◽  
Hematopoietic Progenitor ◽  
Fetal Bone ◽  
Adult Bone Marrow ◽  
Adult Bone

scholarly journals Development of pluripotent hematopoietic progenitor cells in the human fetus

Blood ◽  
1983 ◽  
Vol 62 (1) ◽  
pp. 118-123 ◽  
Author(s):  
IM Hann ◽  
MP Bodger ◽  
AV Hoffbrand
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Progenitor Cells ◽  
Human Fetus ◽  
Fetal Liver ◽  
Hematopoietic Progenitor Cells ◽  
Erythroid Progenitors ◽  
Hematopoietic Progenitor ◽  
Myeloid Progenitor Cells ◽  
Bone Marrow Cultures

Pluripotent hematopoietic progenitor cells (CFU-GEMM), myeloid progenitor cells (CFU-GM), and erythroid progenitors (BFU-E) were studied in midtrimester human fetuses using the mixed colony assay. All three progenitor cell populations were detected at high levels in the fetal liver from 12 to 23 wk of gestation. Stem cells were first observed in the bone marrow at 15–16 wk of gestation, although bone marrow cultures from earlier fetuses showed heavy growths of stromal cells. Spleen cultures first showed growth of stem cells at 18–19 wk, but fetal thymus showed no hematopoietic activity. Peripheral blood from four fetuses aged 13, 18, 20, and 21 wk showed very high levels of all 3 progenitor cells. The results demonstrate that hematopoietic development in the human fetus parallels that of the mouse. The observation that stromal cell development in the bone marrow precedes the appearance of hematopoietic progenitor cells suggests that they may be closely involved in stem cell growth.

scholarly journals Development of pluripotent hematopoietic progenitor cells in the human fetus

Blood ◽  
1983 ◽  
Vol 62 (1) ◽  
pp. 118-123 ◽  
Author(s):  
IM Hann ◽  
MP Bodger ◽  
AV Hoffbrand
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Progenitor Cells ◽  
Human Fetus ◽  
Fetal Liver ◽  
Hematopoietic Progenitor Cells ◽  
Erythroid Progenitors ◽  
Hematopoietic Progenitor ◽  
Myeloid Progenitor Cells ◽  
Bone Marrow Cultures

Abstract Pluripotent hematopoietic progenitor cells (CFU-GEMM), myeloid progenitor cells (CFU-GM), and erythroid progenitors (BFU-E) were studied in midtrimester human fetuses using the mixed colony assay. All three progenitor cell populations were detected at high levels in the fetal liver from 12 to 23 wk of gestation. Stem cells were first observed in the bone marrow at 15–16 wk of gestation, although bone marrow cultures from earlier fetuses showed heavy growths of stromal cells. Spleen cultures first showed growth of stem cells at 18–19 wk, but fetal thymus showed no hematopoietic activity. Peripheral blood from four fetuses aged 13, 18, 20, and 21 wk showed very high levels of all 3 progenitor cells. The results demonstrate that hematopoietic development in the human fetus parallels that of the mouse. The observation that stromal cell development in the bone marrow precedes the appearance of hematopoietic progenitor cells suggests that they may be closely involved in stem cell growth.

Use of Merocyanine 540 for the Isolation of Quiescent, Primitive Human Bone Marrow Hematopoietic Progenitor Cells

1999 ◽  
Vol 8 (2) ◽  
pp. 189-198 ◽  
Author(s):  
Robert E. Pyatt ◽  
Laura L. Jenski ◽  
Ruth Allen ◽  
Ken Cornetta ◽  
Rafat Abonour ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Human Bone ◽  
Human Bone Marrow ◽  
Hematopoietic Progenitor Cells ◽  
Hematopoietic Progenitor ◽  
Merocyanine 540

scholarly journals Functional activity of animal bone marrow cells after their treatment with nanocomplexes

2021 ◽  
Vol 29 (2) ◽  
pp. 9-21
Author(s):  
A. M. Goltsev ◽  
T. G. Dubrava ◽  
Yu. O. Gaevska ◽  
N. M. Babenko ◽  
M. O. Bondarovych ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Toxic Effect ◽  
Progenitor Cells ◽  
Functional Activity ◽  
Therapeutic Dose ◽  
Bone Marrow Cells ◽  
Earth Metal ◽  
Hematopoietic Progenitor Cells ◽  
National Academy Of Sciences ◽  
Hematopoietic Progenitor

Background. Previously, the antitumor activity of nanocomplexes (NCs) containing nanoparticles of rare earth metal orthovanadates GdYEuVO4 and cholesterol has been approved when applied in 9:1 ratio (the cells-to-NCs), which can be considered as a conditionally therapeutic dose. Therefore, studying the potential risks of NCs exposure in terms of functional activity of hematopoietic progenitor cells is relevant. Рurpose – determining a toxic effect of NCs on functional activity of hematopoietic cells of bone marrow (BM). Materials and Methods. The study was performed in BM cells of CBA/H mice. Nanocomplexes were synthesized at Institute for Scintillation Materials of the National Academy of Sciences of Ukraine. BM cells with NCs were incubated in the ratios as follows: 9BM:1NCs; 1BM:1NCs; 1BM:9NCs, followed by assessing the number of apoptotic/necrotic cells in BM using FITC Annexin V Apoptosis Detection Kit I (BD, USA) by means of “FACS Calibur” flow cytometer (“BD”, USA). Hematopoietic progenitor cells of BM were functionally evaluated in vivo by determining the content of colony-forming units of the spleen (CFUs) and the number of myelokaryocytes in lethally irradiated recipients on day 8 after administering BM cells, pre-incubated with NCs. Survival of irradiated recipient mice after BM administration was recorded 12 days long. Results and discussion. The dose-dependent effect of functional potential in- hibition for BM hematopoietic progenitor cells under NCs influence has been established. Although, in vitro processing the BM cells with a conditionally therapeutic dose of NCs (9BM:1NCs) before administration to irradiated animal caused remodeling of cell membranes and contributed to apoptotic manifes- tations, but it did not lead to strong changes in their colony-forming potential and did not reduce the number of BM cells in animals if compared with the introduced BM cells without NCs treatment. Increasing the NCs concentration five- and tenfold significantly reduced the colony-forming potential of BM cells, caused BM hypoplasia and a crucial reduction in the survival of recipient animals, indicating possible toxic effects of this compound when administered at high concentrations. Conclusions. The toxic effect of NCs is detected only when certain concen- trations, significantly exceeding the conditionally therapeutic dose previously determined when treating the experimental oncology diseases, are used.

Sign in / Sign up

Export Citation Format

Share Document